From Cystoscopy to Tumor Genomics: Integrating Urinary Molecular Biomarkers into Personalized NMIBC Surveillance
Medical Sciences · 10.11.2026 · 14 (7) · 768
DOI: 10.3390/medsci14070768 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, online erschienen am 10.11.2026. Verfasst von Guorong Li und 10 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CHU Saint Etienne.
Abstract (Originalsprache)
Non-muscle-invasive bladder cancer (NMIBC) requires lifelong surveillance, traditionally based on repeated cystoscopy and urine cytology, which impose substantial physical, psychological, and economic burdens. Although urinary biomarkers have been extensively investigated as noninvasive alternatives for more than three decades, their potential for clinical adoption has remained largely unrealized. The maturity of validated urinary molecular biomarkers has created new opportunities to reconsider NMIBC surveillance strategies. The urgent question is how these biomarkers can be optimally integrated into clinical practice. We believe that the path forward lies in embracing the biological heterogeneity of NMIBC and tailoring surveillance accordingly. We discuss the emerging potential of clinically available molecular assays, including Bladder EpiCheck, Xpert Bladder Cancer Monitor, and UroDiag, to reduce reliance on routine cystoscopy in selected patients, and propose a practical framework for integrating the molecular biomarkers into tumor biology-based and risk-adapted NMIBC surveillance. We further explore the potential of next-generation liquid biopsy approaches, urinary tumor-derived DNA (utDNA) and urinary extracellular vesicles (uEVs), which may enable tumor genomics-informed residual disease detection and longitudinal monitoring. Rather than replacing cystoscopy, we support a transition from cystoscopy-centred to molecularly informed surveillance, in which the frequency and timing of cystoscopy could be tailored according to individualized clinical and molecular risk. We envisage next-generation liquid biopsy as a natural extension of this approach, representing a continuum from urinary molecular biomarker-guided cystoscopy reduction toward tumor genomics-informed utDNA- and uEV-based surveillance. Such a framework may provide a foundation for progressively more personalized NMIBC surveillance. Its potential to reduce patient burden, improve quality of life, facilitate earlier detection of clinically relevant recurrence, and enable more precise and less invasive monitoring, however, remains to be established through prospective clinical validation.
Förderung
- CHU Saint Etienne
Zitieren
APA
Li, G., Chen, Y., Cornillon, P., Pang, R., Flandrin, P., Campello, P. V., Manel, A., Bali, B., Colombel, M., Neuzillet, Y., & Badet, L. (2026). From Cystoscopy to Tumor Genomics: Integrating Urinary Molecular Biomarkers into Personalized NMIBC Surveillance. Medical Sciences, 14(7), 768. https://doi.org/10.3390/medsci14070768
Vancouver
Li G, Chen Y, Cornillon P, Pang R, Flandrin P, Campello PV, et al. From Cystoscopy to Tumor Genomics: Integrating Urinary Molecular Biomarkers into Personalized NMIBC Surveillance. Medical Sciences. 2026;14(7):768. doi:10.3390/medsci14070768
BibTeX
@article{Li2026,
author = {Li, Guorong and Chen, Yueying and Cornillon, Pierre and Pang, Ran and Flandrin, Pascale and Campello, Pierre Vincent and Manel, Arnaud and Bali, Bruno and Colombel, Marc and Neuzillet, Yann and Badet, Lionel},
title = {From Cystoscopy to Tumor Genomics: Integrating Urinary Molecular Biomarkers into Personalized NMIBC Surveillance},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {7},
pages = {768},
doi = {10.3390/medsci14070768}
}
EUVIMED